All

Cerea Partners enters exclusive negotiations with Seventure Partners to acquire majority stake in Polaris
4 April 2023

Cerea Partners enters exclusive negotiations with Seventure Partners to acquire majority stake in Polaris

Cerea Partners, the investor-partner of the food & beverage universe companies, has entered into exclusive negotiations with a view to acquire a majority stake of Polaris...

Read the press release
MD Anderson and Federation Bio Announce Collaboration to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers
1 February 2023

MD Anderson and Federation Bio Announce Collaboration to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers

Collaboration joins MD Anderson's expertise and capabilities with Fed Bio's proprietary ACT bacterial cell therapy platform to design and manufacture a complex, synthetic...

Read more
Billennium integrates IDnow solution into its Inperly app
12 January 2023

Billennium integrates IDnow solution into its Inperly app

Billennium, a global IT solutions provider for businesses, has announced that it is partnering with IDnow, a leading identity proofing platform provider in Europe. Thanks to...

Read more
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study
5 January 2023

Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study

Domain Therapeutics (“Domain” or “the Company”), a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today...

Read the press release
ErVaccine closes a €4.5 million financing round and prepares to start clinical trial with its first therapeutic cancer vaccine in 2023
5 January 2023

ErVaccine closes a €4.5 million financing round and prepares to start clinical trial with its first therapeutic cancer vaccine in 2023

ErVaccine Technologies, a biotech company and spin-off from the Centre Léon Bérard-Centre de Recherche en Cancérologie de Lyon, which develops next-generation therapeutic...

Read the press release
Ingenico and Izicap announce a strategic partnership
14 December 2022

Ingenico and Izicap announce a strategic partnership

Ingenico and Izicap announce a strategic partnership to bring Izicap’s loyalty solutions to banks and acquirers using PPaaS, Ingenico’s Payments Platform as a Service.

Read more
Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma
12 December 2022

Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma

Enterome, a clinical stage company developing first-in-class immunomodulatory drugs based on its gut bacterial Mimicry drug discovery platform, today announces completion of...

Read more
Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022
7 December 2022

Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its gut bacterial Mimicry drug discovery platform, today...

Read more
SumUp reacts to cost of living with POS kit for small firms
16 November 2022

SumUp reacts to cost of living with POS kit for small firms

SumUp is responding to the cost-of-living crisis by providing small and nano businesses with a new point-of-sale payments solution called POS Lite.

Read more
Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022
16 November 2022

Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022

Enterome announces it will present updated efficacy, immunogenicity and safety data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in...

Read the press release